Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $890.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 5.33% to $890.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $890.0 million through Dec 2025, up 5.33% year-over-year, with the annual reading at $890.0 million for FY2025, 5.33% up from the prior year.
  • Total Non-Current Liabilities hit $890.0 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $891.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $891.1 million in Q3 2025 to a low of $251.8 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $527.7 million across 5 years, with a median of $424.6 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 5.87% in 2021 and later surged 103.87% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $405.1 million in 2021, then grew by 3.73% to $420.2 million in 2022, then rose by 5.2% to $442.0 million in 2023, then skyrocketed by 91.18% to $845.0 million in 2024, then increased by 5.33% to $890.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ANIP at $890.0 million in Q4 2025, $891.1 million in Q3 2025, and $874.7 million in Q2 2025.